Skip to main content

First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

JHOP - Supplements
The Lynx Group: 2021 Ask The Expert .pdf
Please Click the Issue to Download


This resource provides insights from a medical oncologist who specializes in gastric cancer and esophageal cancer. Here you will find information on outcomes from Checkmate 649, a multicenter, randomized, phase 3, open-label study that evaluated OPDIVO plus capecitabine and oxaliplatin (CapeOX) or OPDIVO plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX) compared with CapeOX or FOLFOX alone as first-line therapy in patients with previously untreated, unresectable, advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma without HER2-positive status and an Eastern Cooperative Oncology Group performance status of 0 or 1.

Download to Continue Reading